Pembrolizumab: tested on its own

368 studies: no other medicine in its arm. Page 4 of 4. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.

• A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 InactivationActive, not recruitingNCT04104893Phase 2Report a problem
• Treatment of PD-1 Inhibitor in AIDS-associated PMLStatus unknownNCT04091932Phase 2Report a problem
• Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of AnusActive, not recruitingNCT04046133Phase 1Report a problem
• Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET ScanningActive, not recruitingNCT04009967Phase 2Report a problem
• Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B MutationActive, not recruitingNCT03989089Phase 2Report a problem
• Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine CarcinomaWithdrawnNCT03901378Phase 2Report a problem
• Pembrolizumab for Newly Diagnosed GlioblastomaActive, not recruitingNCT03899857Phase 2Report a problem
• neoadjuvant_thymic Epithelial TumorStatus unknownNCT03858582Phase 2Report a problem
• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid TumorsActive, not recruitingNCT03832569Early Phase 1Report a problem
• Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCCActive, not recruitingNCT03813836Phase 2Report a problem
• Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C MelanomaActive, not recruitingNCT03757689Phase 2Report a problem
• Pembrolizumab in Treating Participants With Recurrent Ovarian CancerActive, not recruitingNCT03732950Phase 2Report a problem
• Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP TrialActive, not recruitingNCT03712605Phase 3Report a problem
• Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial CancerTerminatedNCT03694834Early Phase 1Report a problem
• Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell LymphomasWithdrawnNCT03586024Phase 1/2Report a problem
• Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung CancerWithdrawnNCT03574220Early Phase 1Report a problem
• SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck CarcinomaActive, not recruitingNCT03546582Phase 2Report a problem
• Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNATerminatedNCT03544099Phase 2Report a problem
• Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's SarcomaStatus unknownNCT03469804Phase 2Report a problem
• ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral MetastasesWithdrawnNCT03448666Phase 2Report a problem
• Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.Status unknownNCT03447678Phase 2Report a problem
• Pembrolizumab in Hepatocellular CarcinomaActive, not recruitingNCT03419481Phase 2Report a problem
• Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder CancerWithdrawnNCT03419130Phase 2Report a problem
• Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal AdenocarcinomaCompletedNCT03395847Early Phase 1Report a problem
• A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)Active, not recruitingNCT03385226Phase 2Report a problem
• Chemoradiation vs Immunotherapy and Radiation for Head and Neck CancerActive, not recruitingNCT03383094Phase 2Report a problem
• Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLCStatus unknownNCT03379441Phase 2Report a problem
• Pembrolizumab as Neoadjuvant Treatment in HCCStatus unknownNCT03337841Phase 2Report a problem
• A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin LymphomaCompletedNCT03331731Phase 2Report a problem
• Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid LeukemiaWithdrawnNCT03291353Early Phase 1Report a problem
• Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)CompletedNCT03277638Phase 1/2Report a problem
• Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial CancerCompletedNCT03276013Phase 2Report a problem
• Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cmStatus unknownNCT03254004Phase 2Report a problem
• Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT03245177Phase 1Report a problem
• Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerActive, not recruitingNCT03244384Phase 3Report a problem
• Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of PembrolizumabCompletedNCT03212651Phase 2Report a problem
• Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck CancersTerminatedNCT03193931Phase 2Report a problem
• Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell CarcinomasWithdrawnNCT03189186Phase 1Report a problem
• A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer PatientsStatus unknownNCT03145961Phase 2Report a problem
• Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular SubtypesCompletedNCT03110328Phase 2Report a problem
• Treatment of Relapsed or Refractory Natural Killer/T Cell LymphomaStatus unknownNCT03107962Phase 2Report a problem
• Pembrolizumab Plus Y90 Radioembolization in HCC SubjectsStatus unknownNCT03099564Early Phase 1Report a problem
• A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the ExtremityActive, not recruitingNCT03092323Phase 2Report a problem
• Pembrolizumab for T/NK-cell lymphomasNK-cell LymphomasStatus unknownNCT03021057Phase 2Report a problem
• A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative SurgeryTerminatedNCT03013127Phase 2Report a problem
• Secured Access to Pembrolizumab for Patients With Selected Rare Cancer TypesCompletedNCT03012620Phase 2Report a problem
• Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast CancerCompletedNCT02977468Phase 1Report a problem
• Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT02954874Phase 3Report a problem
• Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the SkinCompletedNCT02883556Phase 2Report a problem
• Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial CancerCompletedNCT02826564Phase 1Report a problem
• Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)Status unknownNCT02779101Phase 2Report a problem
• Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT02769520Phase 2Report a problem
• Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder CarcinomaCompletedNCT02736266Phase 2Report a problem
• Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCCCompletedNCT02707588Phase 2Report a problem
• A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative SurgeryTerminatedNCT02691026Phase 2Report a problem
• Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)CompletedNCT02684292Phase 3Report a problem
• Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator PhenotypeActive, not recruitingNCT02658279Not applicableReport a problem
• Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseCompletedNCT02636010Phase 2Report a problem
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2Report a problem
• A Study of Pembrolizumab for Patients With Thymic Epithelial TumorCompletedNCT02607631Phase 2Report a problem
• A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC PatientsCompletedNCT02599779Phase 2Report a problem
• Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)TerminatedNCT02564380Phase 2Report a problem
• Pembrolizumab in Muscle Invasive/Metastatic Bladder CancerActive, not recruitingNCT02560636Phase 1Report a problem
• Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaActive, not recruitingNCT02359565Phase 1Report a problem
• Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung CancerCompletedNCT02318771Phase 1Report a problem
• Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic CancerStatus unknownNCT02305186Phase 1/2Report a problem
• Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475CompletedNCT02303366Phase 1Report a problem
• Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI CancersTerminatedNCT02268825Phase 1Report a problem

← Pembrolizumab